KKR & Co (NYSE:KKR) will report on Q2 2022.
After Pausing Recruitment, Gossamer Bio Terminates All Studies With CNS Lymphoma Candidate
The FDA placed a partial clinical hold on Gossamer Bio Inc’s (NASDAQ:GOSS) all trials of GB5121 in response to serious adverse events…